ISAL 2019 | Charles Craddock on the latest UK AML trials
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, is taking over the National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working Group. Here, he gives us an update on the latest UK AML trial strategy, including molecular profiling, measurable residual disease detection, and the IMPACT trials transplant clinical trials partnership that is launcing two trials currently: COSI and AMADEUS. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up